Core Viewpoint - The company, 美丽田园医疗健康 (02373), demonstrates confidence in its future prospects through share buybacks and insider purchases, indicating a belief that current share prices do not reflect intrinsic value [1] Group 1: Insider Transactions - Non-executive director Li Fangyu has increased her stake in the company by 52,000 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - From December 1 to the announcement date, Li Fangyu has acquired a total of 114,500 shares, reflecting her strong belief in the company's future development [1] Group 2: Share Buyback Activity - On December 3, 2025, the company repurchased 74,500 shares at a total cost of approximately HKD 1.94285 million, with an average transaction price of about HKD 26.08 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 849,500 shares for approximately HKD 24.636 million [1] Group 3: Management's Perspective - The board believes that the current share price does not reflect the intrinsic value and actual business prospects of the company [1] - The share buyback is seen as a demonstration of management's confidence in the long-term value of the company, which is expected to enhance market value and shareholder returns [1]
美丽田园医疗健康(02373)获非执行董事李方雨增持5.2万股